Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Industry veteran with over two decades of experience to lead expansion across India, South Asia, Southeast Asia, and other high-growth healthcare markets
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
The union minister spoke at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi
Subscribe To Our Newsletter & Stay Updated
